Research report
The tridimensional personality questionnaire as a predictor of response to nefazodone treatment of depression

https://doi.org/10.1016/0165-0327(95)00038-OGet rights and content

Abstract

Personality traits have emerged as the strongest identified predictors of response to antidepressant treatment of major depressive disorder (Peselow et al., 1992; Joyce et al., 1994). 18 subjects in the midst of a major depressive episode were treated with nefazodone in an open trial. All subjects completed Cloninger's tridimensional personality questionnaire (TPQ) before beginning treatment. A multiple regression analysis was performed in an attempt to replicate Joyce et al.'s (1994) finding that temperament type, as assessed by the TPQ, is a strong predictor of antidepressant response. A model involving TPQ reward dependence and harm avoidance scores, and their interaction, was found to significantly predict the response to nefazodone (r2 = 0.47, P < 0.027). When response was defined as a 50% decrease in HAM-D score at last visit, high reward dependence score alone significantly separated responders from nonresponders (Fisher's exact P = 0.050, df = 1). These results raise the intriguing possibility that TPQ scores may have direct clinical applications.

References (33)

  • C.R. Cloninger

    A systematic method for clinical description and classification of personality variants

    Arch. Gen. Psychiatry

    (1987)
  • C.R. Cloninger et al.

    The tridimensional personality questionnaire: U.S. normative data

    Psychol. Rep.

    (1991)
  • M.F. D'Amico et al.

    Placebo-controlled dose-ranging trial designs in phase II development of nefazodone

    Psychopharmacol. Bull.

    (1990)
  • N. Downs et al.

    The relationship of affective illness and personality disorders in psychiatric outpatients

    Ann. Clin. Psychiatry

    (1992)
  • C. Duggan et al.

    Does personality predict long-term outcome in depression?

    Br. J. Psychiatry

    (1990)
  • J. Feighner et al.

    A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression

    Psychopharmacol. Bull.

    (1989)
  • Cited by (0)

    View full text